Alex Schubert — A CPH student who adapted the model to use a single-lead EKG from wearable sensors.
Dr. Goodson — Called on by the chair to speak or respond.
Karen Knudson — Karen Knudson, CEO of the Parker Institute, briefly agrees with the prior remarks and then transitions into her main testimony, emphasizing her support for wearables and introducing cancer as the key issue she wants to discuss.
American Cancer Society — Referenced in connection with cancer screening guidelines and earlier screening ages.
3T Bio — Cited as a Parker Institute portfolio company using AI to refine cancer therapies.
Color Health — Described as using a go-to-employer strategy and a virtual cancer clinic to improve screening and care navigation.
Paradigm Health — Cited as a company using AI to help determine trial suitability and patient matching.
Christopher Ward — Christopher Ward is referenced throughout a continuous committee exchange: he is addressed as Chair, his earlier remarks are cited as the basis for a witness response, he is specifically noted for mentioning the $400 billion and one million jobs figures, and the discussion then transitions to the next slide in the presentation.
Christopher Ward — Addressed as the Chair in the discussion about data privacy and individualized insights.
Christopher Ward — Addressed directly in the discussion about patient access and payment mechanisms for technology.
Dr. Shankar Sundaram — Introduced himself and began testimony on AI, cancer, and health.
Josh Lowenthal — Welcomed as a colleague present for the hearing; invited to ask questions.
Dr. Weber Gupta — Introduced as CEO of Pangea Data and first panelist for panel two.
Jenny Hu — Introduced as senior director for regulatory affairs at Dexcom.
Dr. Danjima Quarles — Introduced as senior director of AI innovation at Lilly Ventures and Eli Lilly.
Dr. James Diggin — Introduced as VP for policy and biosecurity at Twist Biosciences.
Dr. Vibhur Gupta — Dr. Vibhur Gupta explains that care gaps create preventable clinical problems and drive up reimbursement, care, and insurance costs, making the issue both clinically and economically important. He describes Pangea’s approach of using patient records, lab systems, and PACS data to surface intelligence at the point of care and for population health, citing work in chronic kidney disease and COPD that produced positive financial outcomes and savings. He argues that large language models alone are not sufficient for clinical decision-making, and that breaking the workflow into components with different AI models yields better accuracy, repeatability, and trustworthiness. He says this approach has been applied across chronic, rare, and metabolic diseases and published in peer-reviewed journals. He then emphasizes that healthcare tools must be usable, fit clinical workflows, save time, and improve outcomes, noting deployment in health systems in California and across the U.S. Finally, he contrasts enterprise systems with rural practices that may lack EHRs or compute budgets, suggests grants should focus on demonstrating patient-outcome value, and raises broader questions about reimbursement, scaling, and funding for AI technologies that show value in small populations.
Ms. Hu / Ginny Hu — Ginny Hu introduced herself as Senior Director of Regulatory Affairs and Regulatory Science at Dexcom and began her testimony.
Dan Jim Corliss — Dan Jim Corliss introduced himself as a senior director of biotech innovation at Lilly Ventures, the strategic venture arm of Eli Lilly. He added that he works in South San Francisco, has a scientific background with a Ph.D. in biomedicine and computational statistics from UC San Diego and an MBA from Northwestern’s Kellogg School of Business, and joined Lilly about nine months ago to help the company use AI to improve patient lives.
James Diggins — James Diggins introduces himself as leading policy, biosecurity, and trade compliance at Twist Bioscience and chairing the International Gene Synthesis Consortium. He then describes Twist’s gene synthesis capacity, the broad applications of synthetic DNA across biotechnology, agriculture, materials, and resource recovery, and emphasizes that much of this work is domestically manufactured and tied to the U.S. pharmaceutical supply chain. He concludes by beginning to explain how AI is changing biological design at Twist.
Marc Berman — Referenced as the Assembly Member who introduced AB 1864.
AB1864 — AB 1864, introduced by Assembly Member Berman, is discussed as a bill that would require California gene synthesis providers to conduct screening. The speaker notes that this is the kind of screening Twist already performs and supports, and a later witness reiterates support for AB 1864 while urging reliance on federal standards.
Dr. David Magnus — Dr. David Magnus presents Stanford’s approach to oversight and governance of AI in clinical care and research. He explains the FIRM process for evaluating whether AI tools address a real need, including rapid stakeholder interviews, workforce impact review, ethical assessment, and committee oversight for enterprise-wide deployments. He contrasts this with the narrower scope of IRB/FDA review and describes Stanford’s ethics and society review (ESR) process as a way to address broader downstream societal harms, especially for internally funded projects. He notes that ESR has led to meaningful changes in research direction, collaboration, and awareness of privacy and ethical implications, and that Stanford has even rejected at least one proposal. He closes by emphasizing the importance of addressing dual-use, representativeness, equity, and misuse risks early, particularly where AI intersects with biotechnology and other high-risk domains.
Christine Von Rasefeld — Introduced as a board member and community liaison for the Light Collective.
Christine von Raysfeld — Introduced herself as a patient and research advocate and board member/community liaison with the Light Collective.
Rebecca Bauer-Kahan — Addressed as Chair Bauer-Kahan.
Rebecca Bauer-Kahan — The speaker addressed Chair Bauer-Kahan in thanking the committee.
Rebecca Bauer-Kahan — The witness referred to Chair Bauer-Kahan in discussing verification and validation testing.
Chris Ward — Thanked for convening the hearing and referenced as chair.
Chris Ward — The speaker addressed Chair Ward in thanking the committee.
Chris Ward — The witness referred to Chair Ward in discussing verification and validation testing.
Dr. Ida Sim — Dr. Ida Sim introduces herself as a UCSF professor and co-chair in computational precision health, describing her clinical background and the UC Berkeley-UCSF program. She explains that health care should extend beyond the clinic into daily life, and that AI, smartphones, and sensors can support patients between visits and enable care at home. She outlines three research areas in her lab, including remote blood pressure monitoring, and discusses work with CareX to test new technology, its integration into UCSF workflows, and challenges such as EHR integration and avoiding siloed remote monitoring. She concludes by emphasizing that AI is essential for turning large streams of health data into actionable insights and that digital health data must be interoperable across systems, apps, and sensor companies, citing her long-term open-source work on data flow between wearables and electronic health records.
Dr. Karen Knudson — Introduced as the chief executive officer for Parker Institute for Cancer Immunotherapy.
Dr. Shanker Sundaram — Dr. Shanker Sundaram is introduced as the Deputy Principal Associate Director for Mission and Engineering and Director of the Biorealiner at Lawrence Livermore National Laboratory, with a later reference also identifying him in connection with the Bio Resilience Incubator at the same laboratory.
Rebecca Bauer-Kahan — Rebecca Bauer-Kahan, addressed as Chair, was invited to give opening remarks and then thanked for her remarks, forming a brief continuous exchange centered on her role in the meeting.